Posted by Michael Wonder on 30 Jan 2017
Teva announces FDA approval of two new RespiClick maintenance inhalers for the treatment of asthma
30 January 2017 - Approvals expand portfolio of respiratory medicines delivered in RespiClick inhaler designed to eliminate the need for hand-breath coordination during inhalation.
Teva Pharmaceutical Industries today announced that the U.S. FDA approved two products for adolescent and adult patients with asthma. These products, AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick breath-activated, multi-dose dry powder inhaler which is used with other approved medicines in Teva’s respiratory product portfolio.
